Basit öğe kaydını göster

dc.contributor.authorDemir N.
dc.contributor.authorNadaroglu H.
dc.contributor.authorOzkan A.
dc.contributor.authorTasgin E.
dc.contributor.authorIsik C.
dc.contributor.authorDemir Y.
dc.date.accessioned20.04.201910:49:12
dc.date.accessioned2019-04-20T21:44:17Z
dc.date.available20.04.201910:49:12
dc.date.available2019-04-20T21:44:17Z
dc.date.issued2014
dc.identifier.issn1872-3128
dc.identifier.urihttps://dx.doi.org/10.2174/1872312808666140514113838
dc.identifier.urihttps://hdl.handle.net/20.500.12403/818
dc.description.abstractIn this study, serum samples from 50 patients with the diagnosis of Behcet’s disease and 20 healthy volunteers were analyzed. The study consists of three parts. In the first part, paraoxonase (PON) activities were determined in the serum samples of 50 patients with Behcet’s disease and 20 healthy people. In the second part, equal volumes of serum samples from 50 patients were pooled and PON enzymes were purified by using Sepharose-4B-L-tyrosine tyrosine-1-naphtylamine affinity column. Optimum temperature, optimum pH, Vmax and Km values of the pure enzymes were determined. The same purification procedure was also performed in the serum samples of 20 healthy people. Electrophoretic mobility was observed (via SDS-PAGE) in the PON enzymes that were purified from the serum samples of patients with Behcet’s disease and healthy people. In the third part, in vitro effects of drugs containing azathioprine, methylprednisolone and colchicine that have already been used for the treatment of Behcet’s disease were tested on the PON enzymes of the patients with Behcet’s disease and control group. IC50 values and Ki constant values were measured and inhibition types were determined for the drugs containing azathioprine, methylprednisolone and colchicine that have already been used for the treatment of the Behcet’s disease and demonstrate in vitro inhibition effects. ©2014 Bentham Science Publishers.en_US
dc.language.isoengen_US
dc.publisherBentham Science Publishers B.V.
dc.relation.isversionof10.2174/1872312808666140514113838
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAzathioprine
dc.subjectBehcet disease
dc.subjectColchicine
dc.subjectMethylprednisolone
dc.subjectParaoxonase
dc.subjectPurification
dc.subjectaryldialkylphosphatase
dc.subjectarylesterase
dc.subjectazathioprine
dc.subjectcolchicine
dc.subjectmethylprednisolone
dc.subjectsepharose
dc.subjectaryldialkylphosphatase
dc.subjectazathioprine
dc.subjectcolchicine
dc.subjectenzyme inhibitor
dc.subjectmethylprednisolone
dc.subjectPON1 protein, human
dc.subjectArticle
dc.subjectBehcet disease
dc.subjectcontrolled study
dc.subjectdrug blood level
dc.subjectdrug purification
dc.subjectelectrophoretic mobility
dc.subjectenzyme assay
dc.subjecthuman
dc.subjectin vitro study
dc.subjectmajor clinical study
dc.subjectmaximum reaction velocity
dc.subjectpH
dc.subjectpolyacrylamide gel electrophoresis
dc.subjectpriority journal
dc.subjectprotein determination
dc.subjecttemperature
dc.subjectantagonists and inhibitors
dc.subjectBehcet Syndrome
dc.subjectblood
dc.subjectcase control study
dc.subjectenzymology
dc.subjectkinetics
dc.subjectAryldialkylphosphatase
dc.subjectAzathioprine
dc.subjectBehcet Syndrome
dc.subjectCase-Control Studies
dc.subjectColchicine
dc.subjectEnzyme Inhibitors
dc.subjectHumans
dc.subjectKinetics
dc.subjectMethylprednisolone
dc.subjectAzathioprine
dc.subjectBehcet disease
dc.subjectColchicine
dc.subjectMethylprednisolone
dc.subjectParaoxonase
dc.subjectPurification
dc.subjectaryldialkylphosphatase
dc.subjectarylesterase
dc.subjectazathioprine
dc.subjectcolchicine
dc.subjectmethylprednisolone
dc.subjectsepharose
dc.subjectaryldialkylphosphatase
dc.subjectazathioprine
dc.subjectcolchicine
dc.subjectenzyme inhibitor
dc.subjectmethylprednisolone
dc.subjectPON1 protein, human
dc.subjectArticle
dc.subjectBehcet disease
dc.subjectcontrolled study
dc.subjectdrug blood level
dc.subjectdrug purification
dc.subjectelectrophoretic mobility
dc.subjectenzyme assay
dc.subjecthuman
dc.subjectin vitro study
dc.subjectmajor clinical study
dc.subjectmaximum reaction velocity
dc.subjectpH
dc.subjectpolyacrylamide gel electrophoresis
dc.subjectpriority journal
dc.subjectprotein determination
dc.subjecttemperature
dc.subjectantagonists and inhibitors
dc.subjectBehcet Syndrome
dc.subjectblood
dc.subjectcase control study
dc.subjectenzymology
dc.subjectkinetics
dc.subjectAryldialkylphosphatase
dc.subjectAzathioprine
dc.subjectBehcet Syndrome
dc.subjectCase-Control Studies
dc.subjectColchicine
dc.subjectEnzyme Inhibitors
dc.subjectHumans
dc.subjectKinetics
dc.subjectMethylprednisolone
dc.titlePurification of paraoxonase enzyme from the sera of patients with behcet’s disease and analyzing the effects of the drugs containing imuran (azathioprine), prednisolone (methylprednisolone) and colchium (colchicine)en_US
dc.typearticleen_US
dc.relation.journalDrug Metabolism Lettersen_US
dc.contributor.departmentBayburt Universityen_US
dc.contributor.authorID35511537500
dc.contributor.authorID6506121388
dc.contributor.authorID24073665100
dc.contributor.authorID8064145700
dc.contributor.authorID56079018600
dc.contributor.authorID7006472528
dc.identifier.volume8
dc.identifier.issue1
dc.identifier.startpage67
dc.identifier.endpage75
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster